NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)
Patient Death Puts Trial on Hold for Universal CAR-T in Myeloma
The FDA placed a clinical hold on the phase 1 MELANI-01 a dose-escalation study investigating a novel SLAMF7-specific CAR T-cell product in the treatment of patients with relapsed/refractory multiple myeloma after one patient on the trial died from treatment-emergent cardiac arrest.
Cancer Therapy Advisor
